Marker Therapeutics (NASDAQ: MRKR) has announced its participation in a high-profile virtual panel discussion titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?" scheduled for May 28, 2025. CEO Dr. Juan Vera will present the company's MAR-T cell therapy platform, a novel non-engineered multi-antigen approach designed to address CAR-T therapy limitations. The one-hour webcast, produced by Demy-Colton and WBB Research Institute, will feature distinguished panelists including experts from Baylor College of Medicine, University of Colorado, and City of Hope. The event will explore the cell therapy landscape, current limitations of CAR-T therapies, and potential solutions through Marker's innovative approach.
Marker Therapeutics (NASDAQ: MRKR) ha annunciato la sua partecipazione a un importante panel virtuale intitolato "Sette anni dopo l'approvazione FDA – Le cellule CAR-T CD19 hanno soddisfatto le aspettative?", previsto per il 28 maggio 2025. Il CEO, Dr. Juan Vera, presenterà la piattaforma di terapia cellulare MAR-T dell'azienda, un innovativo approccio multi-antigene non ingegnerizzato progettato per superare le limitazioni delle terapie CAR-T. Il webcast di un'ora, prodotto da Demy-Colton e WBB Research Institute, vedrà la partecipazione di rinomati esperti provenienti dal Baylor College of Medicine, University of Colorado e City of Hope. L'evento analizzerà il panorama delle terapie cellulari, le attuali limitazioni delle terapie CAR-T e le possibili soluzioni offerte dall'approccio innovativo di Marker.
Marker Therapeutics (NASDAQ: MRKR) ha anunciado su participación en un panel virtual de alto perfil titulado "Siete años después de la aprobación de la FDA – ¿Han cumplido las células CAR-T CD19 las expectativas?", programado para el 28 de mayo de 2025. El CEO, Dr. Juan Vera, presentará la plataforma de terapia celular MAR-T de la empresa, un novedoso enfoque multiantigénico no modificado diseñado para superar las limitaciones de la terapia CAR-T. La transmisión en línea de una hora, producida por Demy-Colton y WBB Research Institute, contará con panelistas distinguidos, incluidos expertos del Baylor College of Medicine, University of Colorado y City of Hope. El evento explorará el panorama de la terapia celular, las limitaciones actuales de las terapias CAR-T y las posibles soluciones a través del enfoque innovador de Marker.
Marker Therapeutics(NASDAQ: MRKR)는 2025년 5월 28일에 예정된 "FDA 승인 7년 후 – CD19 CAR-T 세포가 기대에 부응했는가?"라는 제목의 고급 가상 패널 토론에 참여한다고 발표했습니다. CEO인 Dr. Juan Vera는 CAR-T 치료의 한계를 극복하기 위해 고안된 새로운 비공학적 다중 항원 접근법인 회사의 MAR-T 세포 치료 플랫폼을 소개할 예정입니다. Demy-Colton과 WBB Research Institute가 제작하는 1시간 분량의 웨비나에는 Baylor College of Medicine, University of Colorado, City of Hope의 전문가들이 포함된 저명한 패널리스트들이 참여합니다. 이번 행사는 세포 치료 분야, 현재 CAR-T 치료의 한계, Marker의 혁신적인 접근법을 통한 잠재적 해결책을 탐구할 것입니다.
Marker Therapeutics (NASDAQ : MRKR) a annoncé sa participation à une table ronde virtuelle de haut niveau intitulée « Sept ans après l'approbation de la FDA – Les cellules CAR-T CD19 ont-elles répondu aux attentes ? », prévue pour le 28 mai 2025. Le PDG, Dr Juan Vera, présentera la plateforme de thérapie cellulaire MAR-T de la société, une approche multi-antigénique non modifiée innovante conçue pour surmonter les limites des thérapies CAR-T. Ce webinaire d'une heure, produit par Demy-Colton et le WBB Research Institute, réunira des panélistes de renom, dont des experts du Baylor College of Medicine, de l'Université du Colorado et de City of Hope. L'événement explorera le paysage des thérapies cellulaires, les limites actuelles des thérapies CAR-T et les solutions potentielles grâce à l'approche innovante de Marker.
Marker Therapeutics (NASDAQ: MRKR) hat seine Teilnahme an einer hochkarätigen virtuellen Podiumsdiskussion mit dem Titel „Sieben Jahre nach FDA-Zulassung – Haben CD19 CAR-T-Zellen die Erwartungen erfüllt?“ angekündigt, die für den 28. Mai 2025 geplant ist. CEO Dr. Juan Vera wird die MAR-T Zelltherapie-Plattform des Unternehmens vorstellen, einen neuartigen nicht gentechnisch veränderten Multi-Antigen-Ansatz, der darauf abzielt, die Einschränkungen der CAR-T-Therapie zu überwinden. Das einstündige Webcast, produziert von Demy-Colton und dem WBB Research Institute, wird renommierte Podiumsteilnehmer umfassen, darunter Experten vom Baylor College of Medicine, der University of Colorado und City of Hope. Die Veranstaltung wird die Zelltherapielandschaft, aktuelle Einschränkungen von CAR-T-Therapien und mögliche Lösungen durch Markers innovativen Ansatz beleuchten.
Positive
None.
Negative
None.
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025
HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled “Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?”. The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT.
This one-hour virtual event will feature insights from leading voices in the cell therapy space, followed by a roundtable discussion. Dr. Vera will present Marker’s MAR-T cell therapy platform as a novel, non-engineered multi-antigen approach designed to address the shortcomings associated with CAR-T cell therapies. Panelists include renowned experts in the cancer field, whose contributions have significantly shaped the field of immuno-oncology:
Helen Heslop, M.D., DSC, Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital
Malcolm Brenner, M.D., Ph.D., Founding Director of the Center for Cell and Gene Therapy and Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics
Manali Kamdar, M.D., Associate Professor, University of Colorado
Geoffrey Shouse, D.O., Ph.D., Assistant Professor, City of Hope
Juan Vera, M.D., President and Chief Executive Officer, Marker Therapeutics
The extensive knowledge and unique perspectives of the panelists promises a profound and impactful discussion.
Virtual Webcast Agenda – May 28, 2025 at 11:00 am – 12:00 pm E.D.T:
11:00 – 11:05 am
Introduction Sara Demy, Founder & CEO, Demy-Colton Steve Brozak, President and Co-founder, WBB Securities
11:05 – 11:10 am
Understanding the Shortcomings of CAR-T Therapy Helen Heslop, MD, Baylor College of Medicine
11:10 – 11:15 am
Overcoming the Current Limitations of CAR-T Therapy Malcolm Brenner, MD, PhD, Baylor College of Medicine
11:15 – 11:20 am
MAR-T Cells as Novel Approach to Address Unmet Needs Juan Vera, MD, Marker Therapeutics
11:20 – 11:50 am
Roundtable Discussion Moderator: Richard Marfuggi, MD, DMH (Medical Director of the WBB Research Institute) Panelists: Geoffrey Shouse, DO, PhD (City of Hoppe) Helen Heslop, MD, DSC (Baylor College of Medicine) Juan Vera, MD (Marker Therapeutics) Malcolm Brenner, MD, PhD (Baylor College of Medicine) Manali Kamdar, MD (University of Colorado)
11:50 – 12:00 pm
Q&A
The roundtable discussion will be accessible online, allowing participants worldwide to join and take part in this crucial dialogue. To attend the roundtable discussion, please register at:
About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.
What is the purpose of Marker Therapeutics' (MRKR) virtual panel discussion on May 28, 2025?
The virtual panel will discuss CD19 CAR-T cell therapy expectations seven years after FDA approval, featuring Marker's MAR-T cell therapy platform as a potential solution to current CAR-T limitations.
Who are the key speakers at MRKR's CAR-T therapy panel discussion?
Key speakers include Dr. Juan Vera (Marker Therapeutics CEO), Dr. Helen Heslop and Dr. Malcolm Brenner (Baylor College of Medicine), Dr. Manali Kamdar (University of Colorado), and Dr. Geoffrey Shouse (City of Hope).
What is Marker Therapeutics' (MRKR) MAR-T cell therapy platform?
MAR-T is a novel, non-engineered multi-antigen approach designed to address the shortcomings associated with traditional CAR-T cell therapies for treating hematological malignancies and solid tumors.
How can investors attend MRKR's virtual roundtable discussion on CAR-T therapies?
Investors can register for the virtual event at Demy-Colton's website: https://virtualsalon.demy-colton.com/2025/05/07/seven-years-after-fda-approval-have-cd19-car-t-cells-met-expectations/
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
